What is the recommended starting dose of losartan (angiotensin II receptor antagonist) for an elderly patient with potential impaired renal function and other comorbid conditions?

Starting Dose for Losartan in the Elderly

The recommended starting dose of losartan in elderly patients is 25 mg once daily, which should be used in those with hepatic impairment or volume depletion; otherwise, the standard 50 mg once daily can be initiated, with no routine dose adjustment required based on age alone. 1

Standard Dosing in Elderly Patients

• The FDA label explicitly states that no overall differences in effectiveness or safety were observed between elderly patients (≥65 years) and younger patients in controlled clinical studies, with 391 patients (19%) aged 65 years and over in hypertension trials. 1

• The standard starting dose remains 50 mg once daily for most elderly patients with hypertension, which can be increased to 100 mg once daily if blood pressure control is inadequate after 4 weeks. 1, 2

• Clinical trials have demonstrated that losartan 50-100 mg daily produces blood pressure reductions of ≤26/20 mm Hg in elderly hypertensive patients, with efficacy comparable to captopril, atenolol, enalapril, felodipine, and nifedipine. 2

Reduced Starting Dose: When to Use 25 mg Daily

The FDA mandates a reduced starting dose of 25 mg once daily in two specific situations: 1

• Patients with mild-to-moderate hepatic impairment (plasma concentrations of losartan are 5 times higher and active metabolite 1.7 times higher than in healthy volunteers) 1

• Patients with volume depletion or renal impairment who are also volume depleted (increased risk of symptomatic hypotension) 1

Renal Impairment Considerations

• No dose adjustment is necessary in elderly patients with renal insufficiency unless they are also volume depleted, despite elevated plasma concentrations of losartan and its active metabolite compared to those with normal renal function. 1

• In hypertensive patients with chronic renal disease (including creatinine clearance 10-29 mL/min and hemodialysis patients), losartan 50-100 mg once daily was effective and well-tolerated, with blood pressure reductions of 14-23/11-18 mm Hg at 12 weeks. 3

• For patients on hemodialysis, losartan 50 mg daily is recommended as first-line therapy, with the option to increase to 100 mg daily if blood pressure control is inadequate. 4

Titration Strategy

Follow this algorithmic approach for dose escalation: 2, 3

1. Week 0-4: Start with 50 mg once daily (or 25 mg if hepatic impairment/volume depletion present)
2. Week 4: If sitting diastolic BP remains ≥90 mm Hg or reduction <5 mm Hg, increase to 100 mg once daily
3. Week 8: If BP goal not achieved, add hydrochlorothiazide 12.5 mg or a second antihypertensive from a different class (calcium channel blocker or beta-blocker preferred)
4. Consider 200 mg daily in patients with proteinuria who do not respond adequately to 100 mg daily, though this exceeds standard FDA-approved dosing 5, 6

Critical Monitoring Parameters

Monitor these parameters closely in elderly patients: 7, 8

• Serum creatinine and potassium within 2-4 weeks after initiation or dose increase 7
• Blood pressure in both sitting and standing positions to detect orthostatic hypotension (elderly are at higher risk) 9
• Discontinue immediately if potassium ≥6.0 mEq/L or reduce dose by half if potassium >5.5 mEq/L 7, 8
• Accept creatinine increases up to 10-20% as physiologic and not requiring discontinuation 8

Common Pitfalls to Avoid

• Do not combine losartan with ACE inhibitors or direct renin inhibitors (substantially increased risk of hyperkalemia, hypotension, and acute kidney injury without additional benefit) 8
• Avoid NSAIDs, potassium supplements, and potassium-sparing diuretics during losartan therapy (increased hyperkalemia risk) 10, 8
• Do not routinely discontinue losartan in patients with GFR <30 mL/min as it remains nephroprotective; only temporarily suspend during acute illness, dehydration, or planned procedures 8
• Losartan provides no cardiovascular benefit in Black patients with left ventricular hypertrophy compared to atenolol, unlike in non-Black patients 1

Tolerability Advantage in Elderly

• Losartan demonstrates superior tolerability compared to other antihypertensives in elderly patients: withdrawal rates due to adverse events were 10-11% with losartan versus 16% with captopril and 23% with atenolol in patients with isolated systolic hypertension. 2

• The risk of first-dose hypotension is low with losartan compared to ACE inhibitors, making it particularly suitable for elderly patients. 2